OncoMatch/Clinical Trials/NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Is NCT04302025 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Alectinib · Entrectinib · Vemurafenib · Cobimetinib · Pralsetinib · Atezolizumab · SBRT · Chemotherapy · Divarasib — This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
ALK fusion
Required: ROS1 fusion
ROS1 fusion
Required: NTRK1 fusion
NTRK1/2/3 fusion
Required: NTRK2 fusion
NTRK1/2/3 fusion
Required: NTRK3 fusion
NTRK1/2/3 fusion
Required: BRAF V600
BRAF V600 mutation
Required: RET fusion
RET fusion
Required: PD-L1 (CD274) (≥ 1% tumor cells)
PD-L1 expression in ≥ 1% tumor cells as determined by FDA-approved test
Required: KRAS G12C
KRAS G12C mutation
Disease stage
Required: Stage IB, IIA, IIB, IIIA, SELECTED IIIB (T3N2 ONLY) (AJCC 8th edition)
Excluded: Stage T4 BY VIRTUE OF MEDIASTINAL ORGAN INVASION, STAGE IIIB BY VIRTUE OF N3 DISEASE
Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
Cannot have received: targeted therapy
Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
Cannot have received: immunotherapy
Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
Cannot have received: radiotherapy
Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Adequate cardiac function to be eligible for surgical resection with curative intent
Adequate hematologic and end-organ function; Adequate cardiac function to be eligible for surgical resection with curative intent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center · Irvine, California
- USC Norris Cancer Center · Los Angeles, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of California Los Angeles - Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify